At the 2024 American Association of Cancer Research Annual Meeting (AACR 2024), Ascentage Pharma (6855.HK) made a significant announcement regarding the latest results from three preclinical studies of their novel drug candidates. The studies focused on olverembatinib, MDM2-p53 inhibitor alrizomadlin (R&D Code: APG-115), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and embryonic ectoderm development (EED) inhibitor APG-5918.
Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, expressed excitement about presenting the preclinical research data at the AACR 2024. The results from these studies are crucial for potential clinical development and therapeutic combinations of the compounds in SDH-deficient neoplasms, prostate cancer, and ovarian cancer.
Olverembatinib, a novel multikinase inhibitor, demonstrated superior antitumor activity in succinate dehydrogenase (SDH)-deficient neoplasms. The study showed promising efficacy in dSDH GIST patients, highlighting its potential for future clinical development in dSDH cancers.
Additionally, the combination of EED inhibitor APG-5918 and MDM2 inhibitor alrizomadlin synergistically inhibited tumor growth in preclinical models of prostate cancer. The study provided insights into the molecular mechanisms of these compounds and their potential for treating patients with PCa.
Furthermore, APG-2449, a novel focal adhesion kinase (FAK) inhibitor, showed promising results in inhibiting metastasis and enhancing the antitumor efficacy of PEGylated liposome doxorubicin (PLD) in epithelial ovarian cancer. The combination treatment demonstrated synergistic antiproliferative effects and prolonged survival times in preclinical models.
Ascentage Pharma, a globally focused biopharmaceutical company, is dedicated to developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. With a robust pipeline of clinical drug candidates and a strong focus on inhibiting protein-protein interactions to restore apoptosis, the company is at the forefront of innovative drug development.
Overall, the results presented at AACR 2024 showcase the potential of Ascentage Pharma’s drug candidates in addressing unmet medical needs in various cancer types and provide a promising outlook for future clinical development.